Top Q3 2011 Healthcare Stocks of This Popular Investment Fund

Following is information about BlackRock Advisors LLC’s top holdings in the Healthcare sector for the period ending September 30th, 2011.

  • Pfizer, Inc. (NYSE:PFE): On 6/30/11 Blackrock Advisors LLC reported holding 56,733,293 shares with a market value of $1,168,705,857. This comprised 1.21% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 59,729,246 shares with a market value of $1,056,013,088. This comprised 1.28% of the total portfolio. The net change in shares for this position over the two quarters is 2,995,953. About the company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Johnson & Johnson (NYSE:JNJ): On 6/30/11 Blackrock Advisors LLC reported holding 13,990,412 shares with a market value of $930,642,159. This comprised 0.96% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 16,325,544 shares with a market value of $1,039,773,875. This comprised 1.26% of the total portfolio. The net change in shares for this position over the two quarters is 2,335,132. About the company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Procter & Gamble Co. (NYSE:PG): On 6/30/11 Blackrock Advisors LLC reported holding 13,204,845 shares with a market value of $839,431,993. This comprised 0.87% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 12,613,242 shares with a market value of $796,904,633. This comprised 0.97% of the total portfolio. The net change in shares for this position over the two quarters is -591,603. About the company: The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Proctor & Gamble’s products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
  • Bristol-Myers Squibb Co. (NYSE:BMY): On 6/30/11 Blackrock Advisors LLC reported holding 32,306,306 shares with a market value of $935,590,592. This comprised 0.97% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 25,045,855 shares with a market value of $785,938,909. This comprised 0.95% of the total portfolio. The net change in shares for this position over the two quarters is -7,260,451. About the company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Merck & Co., Inc. (NYSE:MRK): On 6/30/11 Blackrock Advisors LLC reported holding 19,268,673 shares with a market value of $679,991,488. This comprised 0.70% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 20,008,671 shares with a market value of $654,283,557. This comprised 0.79% of the total portfolio. The net change in shares for this position over the two quarters is 739,998. About the company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • AmerisourceBergen Corporation (NYSE:ABC): On 6/30/11 Blackrock Advisors LLC reported holding 10,171,130 shares with a market value of $421,084,798. This comprised 0.43% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 9,091,394 shares with a market value of $338,836,259. This comprised 0.41% of the total portfolio. The net change in shares for this position over the two quarters is -1,079,736. About the company: AmerisourceBergen Corporation is a pharmaceutical services company. The Company distributes pharmaceutical products and services. AmerisourceBergen distributes an offering of brand name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers.
  • Abbott Laboratories (NYSE:ABT): On 6/30/11 Blackrock Advisors LLC reported holding 6,311,326 shares with a market value of $332,101,967. This comprised 0.34% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 6,621,576 shares with a market value of $338,627,393. This comprised 0.41% of the total portfolio. The net change in shares for this position over the two quarters is 310,250. About the company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Amgen, Inc. (NASDAQ:AMGN): On 6/30/11 Blackrock Advisors LLC reported holding 6,609,874 shares with a market value of $385,686,138. This comprised 0.40% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 6,003,689 shares with a market value of $329,962,742. This comprised 0.40% of the total portfolio. The net change in shares for this position over the two quarters is -606,185. About the company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Biogen Idec, Inc. (NASDAQ:BIIB): On 6/30/11 Blackrock Advisors LLC reported holding 2,828,409 shares with a market value of $302,413,485. This comprised 0.31% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 3,199,723 shares with a market value of $298,054,202. This comprised 0.36% of the total portfolio. The net change in shares for this position over the two quarters is 371,314. About the company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Medtronic, Inc. (NYSE:MDT): On 6/30/11 Blackrock Advisors LLC reported holding 6,540,818 shares with a market value of $252,017,710. This comprised 0.26% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 8,354,343 shares with a market value of $277,698,375. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is 1,813,525. About the company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Eli Lilly & Co. (NYSE:LLY): On 6/30/11 Blackrock Advisors LLC reported holding 8,105,795 shares with a market value of $304,210,476. This comprised 0.31% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 7,314,479 shares with a market value of $270,416,298. This comprised 0.33% of the total portfolio. The net change in shares for this position over the two quarters is -791,316. About the company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Allergan, Inc. (NYSE:AGN): On 6/30/11 Blackrock Advisors LLC reported holding 3,496,160 shares with a market value of $291,055,320. This comprised 0.30% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 3,220,478 shares with a market value of $265,302,969. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is -275,682. About the company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.
  • Baxter International, Inc. (NYSE:BAX): On 6/30/11 Blackrock Advisors LLC reported holding 4,771,688 shares with a market value of $284,822,050. This comprised 0.29% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 4,443,483 shares with a market value of $249,457,133. This comprised 0.30% of the total portfolio. The net change in shares for this position over the two quarters is -328,205. About the company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.
  • Cardinal Health, Inc. (NYSE:CAH): On 6/30/11 Blackrock Advisors LLC reported holding 4,301,345 shares with a market value of $195,367,082. This comprised 0.20% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 5,585,011 shares with a market value of $233,900,267. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 1,283,666. About the company: Cardinal Health, Inc. provides complementary products and services to healthcare providers and manufacturers. The Company’s services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 6/30/11 Blackrock Advisors LLC reported holding 2,556,356 shares with a market value of $123,267,489. This comprised 0.13% of the total portfolio. On 9/30/11, Blackrock Advisors LLC held 6,213,462 shares with a market value of $231,265,063. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 3,657,106. About the company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.

(Note: Data about the fund’s holdings are sourced from whalewisdom.com. Selected financial data are sourced from Google Finance. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet